Results 41 to 50 of about 471 (127)
Background and Objectives: Escherichia coli (E. coli) is an important member of Enterobacteriaceae family involved in severe infections. The increased rate of resistance towards different classes of antibiotics limits their treatment options. The aim of
Ashraf Ahmed Kadry +2 more
doaj +1 more source
Evaluating the health economic impact of cefepime/enmetazobactam in complicated urinary tract infections in the German setting: a cost analysis from payer perspective. [PDF]
Objectives: Complicated urinary tract infections (cUTIs) are ubiquitous, associated with healthcare resources, and demand effective antibiotic treatment to prevent clinical failure and relapse.
Röder J +8 more
europepmc +2 more sources
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]
Objectives: To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to
Tascini C +3 more
europepmc +2 more sources
<i>In vitro</i> activity of cefepime/zidebactam against <i>Klebsiella pneumoniae</i> carrying <i>bla</i> <sub>KPC</sub> variants conferring resistance to ceftazidime/avibactam. [PDF]
Objectives: Resistance to ceftazidime/avibactam among KPC-producing Klebsiella pneumoniae (KPC-Kp) is often due to mutations within the bla KPC gene, determining a widespread occurrence of novel variants.
Tascini C +3 more
europepmc +2 more sources
Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations ...
Po-Yu Liu +23 more
doaj +1 more source
Cefepime/Enmetazobactam. [PDF]
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees.
Staten AR, Baker DE.
europepmc +3 more sources
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez +4 more
wiley +1 more source
Background The emergence and spread of multidrug‐resistant Enterobacteriaceae (MDR‐E) in community and hospital settings constitute a major public health challenge, particularly in densely populated urban areas. Although antimicrobial resistance among clinical isolates has been repeatedly studied, resistance profiles of intestinal carriage strains ...
Kobina Amandzé Adams Kofi +8 more
wiley +1 more source
P100 Validation of cefepime/enmetazobactam on Bruker AST devices [PDF]
Abstract Objectives To evaluate the feasibility and manufacturing robustness of integrating the novel β-lactam/β-lactamase inhibitor combination cefepime/enmetazobactam (FEP/META) which has been approved by FDA, EMA and MHRA, into Bruker’s antimicrobial susceptibility testing (AST) devices ...
Ward, Jon +5 more
europepmc +2 more sources
This review highlights computational approaches for discovering antimicrobials against carbapenem‐resistant Enterobacterales. It outlines methods like pharmacophore modeling, molecular docking, and absorption, distribution, metabolism, and excretion–toxicity (ADMET) analysis, integrated with in vitro assays, to identify and validate potential drugs ...
Muhammad Absar +7 more
wiley +1 more source

